Changes in Activated Thrombin-Activatable Fibrinolysis Inhibitor Levels Following Thrombolytic Therapy in Ischemic Stroke Patients Correlate with Clinical Outcome
Marie‐Christine Alessi(Hôpital de la Timone), Norbert Nighoghossian(Université Claude Bernard Lyon 1), Philippe Grosjean(Sanofi (France)), Laurent Derex(Centre National de la Recherche Scientifique), Vincent Larrue(Université Fédérale de Toulouse Midi-Pyrénées), Anna Mezzapesa(Apple (Israel)), Joan Montaner(Universitat Autònoma de Barcelona), Tae‐Hee Cho(Lyon 1 Université), Serge Timsit(Hôpital Maison Blanche), Laurent Suissa(Inserm), Mar Castellanos(Universidade da Coruña), Christophe Gaudin(Sanofi (Mexico)), Yves Donazzolo(European Organisation for Rare Diseases), Raf Brouns(Vrije Universiteit Brussel), Igor Sibon(Inserm), Mathieu Zuber(Université Paris Cité), Marie‐Hélène Mahagne(Hôpital Pasteur), Laura Mechtouff(Hospices Civils de Lyon), Valérie Martin(Sanofi (France)), Pierre Suchon(Inserm)
Cited by 17
Related Papers
MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset
|New England Journal of Medicine|2018|1.3k
Effect of Dronedarone on Cardiovascular Events in Atrial Fibrillation
|New England Journal of Medicine|2009|1.1k
Treatment for Adult HIV Infection
|JAMA|2006|1k
Antiretroviral Therapy in Adults
|JAMA|2000|1k
Antiretroviral Treatment of Adult HIV Infection
|JAMA|2008|1k